Show simple item record

Opinion: PARP inhibitors in cancer-what do we still need to know?

dc.contributor.authorWicks, AJ
dc.contributor.authorKrastev, DB
dc.contributor.authorPettitt, SJ
dc.contributor.authorTutt, ANJ
dc.contributor.authorLord, CJ
dc.coverage.spatialEngland
dc.date.accessioned2022-09-09T13:21:30Z
dc.date.available2022-09-09T13:21:30Z
dc.date.issued2022-07-01
dc.identifier.citationOpen Biology, 2022, 12 (7), pp. 220118 -en_US
dc.identifier.issn2046-2441
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5437
dc.identifier.eissn2046-2441
dc.identifier.eissn2046-2441
dc.identifier.doi10.1098/rsob.220118
dc.description.abstractPARP inhibitors (PARPi) have been demonstrated to exhibit profound anti-tumour activity in individuals whose cancers have a defect in the homologous recombination DNA repair pathway. Here, we describe the current consensus as to how PARPi work and how drug resistance to these agents emerges. We discuss the need to refine the current repertoire of clinical-grade companion biomarkers to be used with PARPi, so that patient stratification can be improved, the early emergence of drug resistance can be detected and dose-limiting toxicity can be predicted. We also highlight current thoughts about how PARPi resistance might be treated.
dc.formatPrint-Electronic
dc.format.extent220118 -
dc.languageeng
dc.language.isoengen_US
dc.publisherThe Royal Societyen_US
dc.relation.ispartofOpen Biology
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectPARP inhibitors
dc.subjectbiomarkers
dc.subjectcancer
dc.subjectdrug resistance
dc.subjectsynthetic lethality
dc.subjectDrug Resistance, Neoplasm
dc.subjectHumans
dc.subjectNeoplasms
dc.subjectPoly(ADP-ribose) Polymerase Inhibitors
dc.titleOpinion: PARP inhibitors in cancer-what do we still need to know?en_US
dc.typeJournal Article
dcterms.dateAccepted2022-07-01
dc.date.updated2022-09-09T12:48:13Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1098/rsob.220118en_US
rioxxterms.licenseref.startdate2022-07-01
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/35892198
pubs.issue7
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Gene Function
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Gene Function
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/20/21 Starting Cohort
pubs.publication-statusPublished
pubs.publisher-urlhttp://dx.doi.org/10.1098/rsob.220118
pubs.volume12
icr.researchteamGene Functionen_US
dc.contributor.icrauthorWicks, Andrew
dc.contributor.icrauthorLord, Christopher
icr.provenanceDeposited by Ms Alexandra Carroll (impersonating Prof Chris Lord) on 2022-09-09. Deposit type is initial. No. of files: 1. Files: Opinion PARP inhibitors in cancer-what do we still need to know.pdf


Files in this item

Thumbnail
Name:
Opinion PARP inhibitors in ...
Size:
701.6Kb
Format:
PDF
View/Open

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/